Nanoform Finland Oyj Valuation

Is NANOFH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NANOFH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NANOFH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NANOFH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NANOFH?

Key metric: As NANOFH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NANOFH. This is calculated by dividing NANOFH's market cap by their current revenue.
What is NANOFH's PS Ratio?
PS Ratio	43.7x
Sales	€2.43m
Market Cap	€108.11m

NANOFH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	27.8x
Enterprise Value/EBITDA	-3.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NANOFH's PS Ratio compare to its peers?

The above table shows the PS ratio for NANOFH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.8x
PCA PCAS	0.5x	n/a	€109.9m
CELL PhenomeX	1.4x	23.4%	US$99.6m
ALECR Eurofins-Cerep	2.3x	n/a	€100.9m
6986 HeXun Biosciences	14.9x	n/a	NT$3.5b
NANOFH Nanoform Finland Oyj	43.7x	55.7%	€106.1m

Price-To-Sales vs Peers: NANOFH is expensive based on its Price-To-Sales Ratio (43.7x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does NANOFH's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: NANOFH is expensive based on its Price-To-Sales Ratio (43.7x) compared to the European Life Sciences industry average (4.5x).

Price to Sales Ratio vs Fair Ratio

What is NANOFH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NANOFH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	43.7x
Fair PS Ratio	29.1x

Price-To-Sales vs Fair Ratio: NANOFH is expensive based on its Price-To-Sales Ratio (43.7x) compared to the estimated Fair Price-To-Sales Ratio (29x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NANOFH forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€1.24	€3.50 +182.3%	14.3%	€4.00	€3.00	n/a	2
Dec ’25	€1.50	€3.50 +133.3%	14.3%	€4.00	€3.00	n/a	2
Sep ’25	€1.85	€4.25 +129.7%	5.9%	€4.50	€4.00	n/a	2
Aug ’25	€1.78	€4.25 +138.8%	5.9%	€4.50	€4.00	n/a	2
Jul ’25	€1.66	€4.25 +155.4%	5.9%	€4.50	€4.00	n/a	2
Jun ’25	€1.97	€4.25 +116.2%	5.9%	€4.50	€4.00	n/a	2
May ’25	€2.15	€4.40 +104.7%	2.3%	€4.50	€4.30	n/a	2
Apr ’25	€2.71	€4.40 +62.4%	2.3%	€4.50	€4.30	n/a	2
Mar ’25	€3.01	€4.40 +46.2%	2.3%	€4.50	€4.30	n/a	2
Feb ’25	€2.86	€4.40 +53.8%	2.3%	€4.50	€4.30	n/a	2
Jan ’25	€1.59	€4.40 +177.6%	2.3%	€4.50	€4.30	n/a	2
Dec ’24	€1.67	€4.40 +163.5%	2.3%	€4.50	€4.30	€1.50	2
Nov ’24	€1.57	€6.00 +282.2%	8.3%	€6.50	€5.50	€1.30	2
Oct ’24	€1.78	€6.00 +237.1%	8.3%	€6.50	€5.50	€1.57	2
Sep ’24	€2.30	€6.00 +160.9%	8.3%	€6.50	€5.50	€1.85	2
Aug ’24	€1.79	€7.00 +292.2%	21.4%	€8.50	€5.50	€1.78	2
Jul ’24	€1.91	€7.00 +266.5%	21.4%	€8.50	€5.50	€1.66	2
Jun ’24	€2.16	€7.00 +224.1%	21.4%	€8.50	€5.50	€1.97	2
May ’24	€2.24	€7.15 +219.2%	23.1%	€8.80	€5.50	€2.15	2
Apr ’24	€1.59	€7.15 +349.7%	23.1%	€8.80	€5.50	€2.71	2
Mar ’24	€2.15	€7.15 +232.6%	23.1%	€8.80	€5.50	€3.01	2
Feb ’24	€2.99	€8.88 +197.3%	12.7%	€10.00	€7.75	€2.86	2
Jan ’24	€3.20	€8.88 +177.3%	12.7%	€10.00	€7.75	€1.59	2
Dec ’23	€3.06	€8.88 +190.0%	12.7%	€10.00	€7.75	€1.67	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.